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doi:10.1
1168Objective: Hiatal hernia is common in patients with Barrett’s esophagus. We sought to evaluate the effect of
hiatal hernia size and initial columnar segment length on the success of radiofrequency ablation of Barrett’s
esophagus.
Methods: A phase II clinical trial was conducted aimed at evaluating the success of radiofrequency ablation in
eradicating Barrett’s esophagus. Success was defined as complete replacement of the columnar lining with squa-
mous mucosa and lack of intestinal metaplasia using light microscopy. Hiatal hernia size and columnar segment
length were measured endoscopically.
Results: Sixty-seven patients were accrued to the protocol. In the 55 patients who completed radiofrequency
ablation (43 successes, 12 failures), the mean hiatal hernia size was 3.3 cm (range, 0–10 cm), and the mean co-
lumnar segment length was 5.4 cm (range, 1–18 cm). The median length of the columnar segment was 3 cm in
the successful cases and 8.5 cm in the failed cases (P¼ .002). Although the median hiatal hernia size was iden-
tical in the successful and failed cases (3 cm, P¼ .38), the median hiatal hernia size was 7 cm (P¼ .001) in the 6
patients who experienced nonhealing after the initial ablation. Patients who were successfully ablated but had
larger hiatal hernias and longer columnar segment lengths required significantly more radiofrequency ablation
sessions than those with smaller hernias and shorter segments (P ¼ .003 and P ¼ .007, respectively).
Conclusions: Patients with larger hiatal hernias and longer columnar segments aremore likely to experience fail-
ure or nonhealing after radiofrequency ablation. These patients also require more radiofrequency ablation treat-
ments to achieve successful eradication of Barrett’s esophagus. (J Thorac Cardiovasc Surg 2011;142:1168-73)Barrett’s esophagus (BE) is a premalignant condition of the
esophagus characterized by columnar metaplasia. Patients
with BE are thought to have an increased risk of developing
esophageal adenocarcinoma when compared with the gen-
eral population.1 Radiofrequency ablation (RFA) is a tech-
nology that has been developed to eradicate BE, replacing it
with normal, stratified, squamous epithelium. Published
literature reports that the success rate of RFA in eradicating
BE ranges from approximately 45% to 100%2-12; however,
characteristics of challenging and failed cases using RFA
have not been clearly delineated. In addition, there
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The Journal of Thoracic and Cardiovascular Surusing this technology in the published literature. We
conducted a phase II, prospective, single institution, pilot
clinical trial aimed at evaluating the success of RFA in
eradicating BE, with emphasis placed on the impact of
hiatal hernia size and initial columnar segment length on
the likelihood of a successful outcome.
MATERIALS AND METHODS
Clinical Trial Design
A single-arm, phase II trial of RFA for BE was conducted at a single in-
stitution after approval by the institutional review board. All patients with
BEwere eligible, regardless of the presence or absence of dysplasia, and all
signed informed consent. BE was defined as an esophageal columnar seg-
ment greater than 3 cm in length regardless of whether or not intestinal
metaplasia (IM) was detected by biopsy or an esophageal columnar seg-
ment less than 3 cmwith biopsy-proven IM. Patients with a squamous lined
tubular esophagus, with biopsies of the gastroesophageal junction showing
only IM (termed ‘‘IM of the gastroesophageal junction’’) were not eligible,
as were those who could not tolerate proton pump inhibitors. Patients who
underwent prior fundoplication were eligible.
All patients underwent standardized video endoscopic assessment of BE
before enrollment, which included white light and narrow band imaging
(NBI), as well as 4-quadrant biopsies performed at 1- to 2-cm intervals
throughout the columnar segment using jumbo biopsy forceps (Radial
jaw 4; Boston Scientific, Natick, Mass). Hiatal hernias were sized by endo-
scopically measuring the distance from the incisors to the top of the gastric
folds and subtracting this figure from the corresponding measurement ofgery c November 2011
st
n
eit
aPf
o
r
eb
m
u
N
0
1
2
3
4
5
6
7
8
9
10
11
12
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Initial length of Barrett’s Segment (cm)
st
n
eit
aPf
o
r
eb
m
u
N
Hiatal Hernia Size (cm)
0
5
10
15
20
0 1 2 3 4 5 6 7 8 9 10
Pr
ev
iou
s
Fu
nd
op
lic
at
ion
FIGURE 1. Distribution of initial BE length and hiatal hernia size in 67
enrolled patients. A, Initial BE length. B, Hiatal hernia size.
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
IM ¼ intestinal metaplasia
NBI ¼ narrow band imaging
RFA ¼ radiofrequency ablation
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Sthe position of the crural pinch. Patients with visible lesions in their colum-
nar segment had these removed using endoscopic mucosal resection
(Duette, Wilson-Cook, Bloomington, Ind) before ablation. Endoscopic ul-
trasonography was not performed. Patients with T1a carcinomas were still
eligible for inclusion provided that the endoscopic mucosal resection mar-
gins were negative, and computed tomography of the chest and positron
emission tomography were negative for metastatic disease. Patients with
T1b or deeper carcinomas were not eligible for inclusion. A minimum of
2 months was allowed to pass between the endoscopic mucosal resection
procedure (if performed) and the first ablation.
Ablation Protocol
All ablations were performed using the HALO system (BARRX Medi-
cal Inc, Sunnyvale, Calif), following strict adherence to the manufacturer’s
instructions. Ablations were performed in the endoscopy suite under con-
scious sedation, unless it was deemed unsafe by the ablating physician or
anesthesiologist. In these later cases, the ablation was performed in the op-
erating room under general anesthesia using an endotracheal tube and me-
chanical ventilation. A single investigator (R.J.K.) performed or assisted in
all ablation procedures. In general, columnar segments greater than 3 cm in
length were initially ablated using the HALO 360 system, and shorter seg-
ments were ablated using the HALO 90 system, although this decision was
ultimately left up to the physician performing the ablation. The HALO 90
devicewas used to ablate the remaining ‘‘islands’’ of BE left over after a cir-
cumferential treatment. At least 8 weeks were allowed to elapse after each
ablation procedure before another ablation was performed. The time period
needed to complete RFA (in months) was therefore equal to the number of
required RFA sessions multiplied by 2months. All patients had their proton
pump inhibitor dose doubled during the ablation period, and those not ini-
tially taking proton pump inhibitors were placed on a twice daily regimen.
The number of ablation sessions was not limited in this protocol. A
given patient’s treatment was considered completed when one of the fol-
lowing criteria was met:
 Voluntary withdrawal from the protocol for any reason.
 Failure of ablation as determined by the principal investigator (RJK).
 Successful ablation. A patient was considered successfully ablated if the
tubular esophagus was completely eradicated of columnar lining as as-
sessed by white light and NBI, and all biopsies obtained from the tubular
esophagus lacked IM.
For the intention-to-treat analysis, all patients who met criteria for com-
pletion and were not successful, as described above, were considered
failures.
The performance of hiatal hernia repair and fundoplication was left up
to the discretion of the principal investigator (R.J.K.). In general, surgical
repair was offered to those patients with poor symptom control on proton
pump inhibitors or those who exhibited nonhealing after an initial ablation
attempt, regardless of hiatal hernia size or columnar segment length.
Data Collection
Data collected on initial entry into the protocol included patient demo-
graphics, length of BE, size of hiatal hernia, proton pump inhibitor dose,
and dysplasia (or carcinoma) status. Data collected during the ablationThe Journal of Thoracic and Carperiod included the number of ablation sessions per patient, ablation device
(HALO 360 vs 90), compliance with proton pump inhibitor therapy, and
percent of columnar mucosa successfully ablated with each session.
Statistical Analysis
Pearson’s correlation coefficient (r) was used to quantify the relation-
ship between hiatal hernia size and initial columnar segment length. The
nonparametric Wilcoxon Mann–Whitney test was used to determine the
significance of the differences between median values of hiatal hernia
size/initial columnar segment length for RFA successes, failures, and non-
healing patients. The nonparametric Kruskal–Wallis test was used to deter-
mine the significance of the effect of hiatal hernia size/initial columnar
segment length on the number of ablation sessions needed to achieve suc-
cess. IBM SPSS Statistics software (version 19; SPSS Inc, Chicago, Ill)
was used for all analyses.RESULTS
Patient Characteristics
Sixty-seven patients signed informed consent andwere ac-
crued into this phase II trial. Forty-six patients were male
(69%), and the mean age was 59.3 years (range, 24–85
years). Figure 1 demonstrates the distribution of Barrett’s
segment length and hiatal hernia size of all 67 patients.Hiatal
hernia size was not significantly correlated with the initial
length of BE in these 67 patients (r ¼ .18, P ¼ .15). Forty-
eight patients (72%) had no dysplasia, 5 patients had low-
grade dysplasia (7.5%), 6 patients had high-grade dysplasiadiovascular Surgery c Volume 142, Number 5 1169
TABLE 1. Causes of failure of radiofrequency ablation for Barrett’s
esophagus
Cause No. of patients
Insurance coverage denial 3
Other medical issues
Progression of cardiac disease 1
Development of breast cancer 1
Motor vehicle accident 1
Voluntarily withdrew from protocol 2
Repeated nonhealing after ablation 3
Progression* 1
*Patient with multifocal high-grade dysplasia in whom raised lesions developed ne-
cessitating esophagectomy.
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S(9%), 1 patient had T1a adenocarcinoma (1.5%), and 6 pa-
tients were indefinite for dysplasia (9%). Fifty-five patients
met the criteria for the completion of treatment as defined
in the ‘‘Materials and Methods,’’ and 12 patients are still ac-
tively being treated.
A total of 179 RFA treatment sessions were performed in
these 67 patients. There were 54 HALO 360 procedures and
125 HALO 90 sessions. A total of 167 procedures were per-
formed in the endoscopy suite under conscious sedation
(93%), and the remaining 12 procedures were performed
in the operating roomwith patients under general anesthesia
because of difficult airway management under conscious
sedation. The initial ablation was performed using the
HALO 360 device in 43 patients (64%), and the HALO
90 device was used initially in 24 patients.
Six patients underwent hiatal hernia repair and fundopli-
cation. In 3 patients, symptom control was poor before RFA
initiation, resulting in surgical repair before ablation. In 3
others, surgical repair was performed after the first ablation
attempt resulted in nonhealing, in an attempt to better con-
trol esophageal exposure to acid.Success of Radiofrequency Ablation in Eradicating
Barrett’s Esophagus
According to the intention-to-treat principle, 43 of 55 pa-
tients who completed RFA had a successful result as defined
in the ‘‘Materials andMethods,’’ yielding an overall success
rate of 78%. Figure 2 shows the effect of initial BE length
and hiatal hernia size on the success of RFA. The median
initial BE lengths were significantly different between the)
mc(
ezis
ai
nr
ehl
at
aih
n
aid
e
M 0
1
2
3
4
5
6
7
8
9
)m
c(
ht
gn
el
EB
la
iti
ni
n
ai
de
M
Success
n=43
Failure
n=12
0
1
2
3
4
5
6
7
8
9
FIGURE 2. Effect of hiatal hernia size and initial columnar segment
length on the ability to successfully ablate BE in the 55 patients who com-
pleted therapy. Compared with successfully ablated patients, patients who
failed ablation had significantly longer initial BE segments (8.5 vs 3 cm;
P ¼ .002). No significant difference was seen between the successes and
failures according to median hiatal hernia size (P ¼ .38) when analyzed
by intention to treat. BE, Barrett’s esophagus.
1170 The Journal of Thoracic and Cardiovascular Sursuccesses and failures (P ¼ .002), but this difference was
not appreciated when hernia size was evaluated (P ¼ .38).
As demonstrated in Table 1, 8 of 12 failures resulted from
the inability to continue with the protocol for reasons not di-
rectly attributable to RFA itself. Only 4 patients demon-
strated true failure of the technology, manifested by
progression of disease or failure to heal appropriately after
circumferential ablation, giving a ‘‘per protocol’’ success
rate of 43 of 47 patients (91%).
For the 43 patients successfully ablated, the median num-
ber of ablations necessary to achieve success was 2 (range,
1–8). Figure 3 demonstrates the effect of initial Barrett’s
segment length and hiatal hernia size on the number of ab-
lation sessions needed to achieve success in these patients.
Patients with longer columnar segment lengths and larger
hiatal hernias required more RFA treatment sessions than
those with shorter segments and smaller hernias
(P ¼ .007 and .003, respectively).Nonhealing of the Ablated Segment
Of the 55 initial ablations performed in the successfully
ablated patients, 6 (11%) resulted in nonhealing of the ab-
lated segment 2 months later despite compliance with dou-
bling of proton pump inhibitor dose and frequency as
recommended by the manufacturer. Nonhealing was char-
acterized endoscopically by replacement of the ablated
area with an eschar, with no regeneration of mucosa. After
2 more months of follow-up, all patients were noted to have
healed with recurrent columnar lining in the ablated seg-
ment. The median initial BE length in these patients was
8.5 cm (range, 5–11 cm), and the median hiatal hernia
size was 7 cm (range, 3–10 cm). Table 2 demonstrates the
clinical features and outcome of these 6 patients, and
Figure 4 shows the effect of initial BE length and hiatal her-
nia size on the occurrence of nonhealing. The median initial
BE lengths and hiatal hernia sizes were significantly differ-
ent between the patients who were able to heal their mucosa
and the nonhealing patients (P ¼ .015 and .001, respec-
tively). All cases of nonhealing occurred after ablation
with the HALO 360 device.gery c November 2011
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FIGURE 3. Effect of initial BE length and hiatal hernia size on the num-
ber of RFA sessions necessary for BE eradication in the 43 successfully ab-
lated patients. A, Box and whisker plot of the number of RFA sessions
needed to successfully eradicate BE according to the initial length of the
columnar segment (P ¼ .007). The upper and lower ends of each box rep-
resent the upper and lower quartiles, the thick horizontal bar represents the
median, and the extreme horizontal bars represent the maximum and min-
imum values. B, Box and whisker plot of the number of RFA sessions
needed to successfully eradicate BE according to hiatal hernia size
(P ¼ .003). The upper and lower ends of each box represent the upper
and lower quartiles, the thick horizontal bar represents the median, and
the extreme horizontal bars represent the maximum and minimum values.
RFA, Radiofrequency ablation.
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SDISCUSSION
RFA for Barrett’s esophagus is a relatively new technol-
ogy that possesses the advantage of enhanced precision over
previous ablative approaches. As a result, efficacy seems toTABLE 2. Clinical features and outcome in 6 patients with nonhealing aft
Patient no. Age (y)/gender Initial BE length (cm) Hiatal h
1 47/M 10
2 53/F 9
3 72/M 11
4 54/M 8
5 67/M 7
6 60/M 5
*Moved out of area. yDeveloped metastatic breast cancer. zFurther increased proton pump
bition. kUnder surveillance using endoscopy and biopsies.
The Journal of Thoracic and Carbe maximized, and adverse events are minimized compared
with other ablation techniques, such as photodynamic ther-
apy.13 Although many published reports regarding the use
of RFA for BE exist, only a small number of these are pro-
spective clinical trials.2-8 Formal prospective clinical trials
provide the most robust data compared with retrospective
and prospective case series because of their scientific
rigor. With this as a background, we designed and
performed a phase II, single-arm trial of RFA for BE.
Success of Radiofrequency Ablation in Eradicating
Barrett’s Esophagus
Current literature indicates that the success of RFA in the
eradication of BE ranges from approximately 45% to
100%.2-12 In the present study, the success of RFA in
eradicating BE was 78% when analyzed according to the
intention to treat, which mirrors the success rate
published in the largest RFA trial to date.2 One explanation
for thewide range of success rates in the published literature
is variation in ablation protocols, especially with regard to
a predetermined maximum number of ablations. In the pres-
ent trial, no predetermined limit was set on the maximum
number of ablation sessions to determine the actual number
of ablations necessary to achieve success in any given
patient.
Another factor that may influence the reported success
rates of RFA is the variable use of NBI after ablation.
Many of the previously published trials evaluating RFA
did not mandate the use of NBI or mention its use in the cor-
responding publication.2,3,6,7 In the present study, the
protocol mandated the use of NBI, where it was not
unusual for NBI to detect very small islands of columnar
mucosa that went undetected under white light. In these
cases, patients were re-ablated, using NBI as a guide.
Impact of Hiatal Hernia Size and Columnar Segment
Length on the Success of Radiofrequency Ablation
In the present clinical trial, the length of the initial colum-
nar segment affected both the ability to perform a successful
ablation and the number of ablations needed to achieve suc-
cess. This finding has also been alluded to in other published
studies.2,14,15 Although the increased surface area of the
columnar mucosa in the patients with longer segmentser initial ablation
ernia size (cm) Further interventions Outcome
3 None Withdrew from trial*
7 None Withdrew from trialy
6 Re-ablationz Failurek
7 Re-ablationx Failurek
10 Re-ablationz Failurek
8 Re-ablationz Success
inhibition and performed hiatal hernia repair. xFurther increased proton pump inhi-
diovascular Surgery c Volume 142, Number 5 1171
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FIGURE 4. Effect of hiatal hernia size and initial columnar segment
length on the phenomenon of nonhealing after RFA for BE in the 55 pa-
tients who completed therapy. Patients in whom the initial ablation resulted
in nonhealing had significantly longer BE segments (8.5 vs 3 cm; P¼ .015)
and significantly larger hiatal hernias (7 vs 2 cm; P¼ .001) than those who
were able to heal their ablated segment after the initial RFA session. BE,
Barrett’s esophagus.
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Smay be responsible for this observation, another possible
explanation may be that patients with longer columnar
segments may have more severe reflux or an inherent
propensity to form BE. The fact that the patients with
longer segments also were more likely to experience the
phenomenon of nonhealing after their initial ablation
supports the latter of the 2 explanations.
Similar to initial columnar segment length, hiatal hernia
size also affected the ability to successfully ablate BE. Al-
though the ability to achieve success (Figure 2) did not
seem to be affected, hiatal hernia size clearly seemed to affect
the likelihood of nonhealing after initial ablation (Figure 4),
as well as the number of ablations needed to achieve success
(Figure 3). To our knowledge, this has not been reported. A
possible explanation for this finding may be that larger, slid-
ing hernias present an anatomic challenge for theHALO sys-
tem, inasmuch as the esophagus may be somewhat tortuous
in its course and the gastroesophageal junction may move
significantly up and down. As with the initial columnar seg-
ment length, a larger hiatal hernia may also simply be
a marker for more severe reflux disease, which may in turn
affect success rates of RFA. For patients with large, severely
symptomatic hiatal hernias and long, dysplastic columnar
segments, esophagectomy may be a viable option. Modern,
minimally invasive operative approachesmay be particularly
suitable for this population of patients.Nonhealing of the Esophagus After Radiofrequency
Ablation
Nonhealing, as defined in the ‘‘Results,’’ represented the
major reason for the technical failure of the HALO system1172 The Journal of Thoracic and Cardiovascular Surin the present clinical trial. Patients with both long colum-
nar segment lengths and large hiatal hernia sizes seemed
to be predisposed to failure in this fashion. The phenome-
non of nonhealing is not well described in the published lit-
erature. A recent publication by Herrero and colleagues16
described a series of patients with columnar segments
greater than 10 cm and found similar nonhealing in 4 of
26 patients (15%). Pouw and colleagues3 also reported
a single patient (of 23) with a long columnar segment that
‘‘did not regenerate squamous mucosa’’ after ablation.3 In
the present study, the frequency of nonhealing was 6 of
67 initial ablations (9%).
The reason for nonhealing remains unknown. Herrero
and colleagues16 hypothesized that these patients may
have had poor reflux control. In the present trial, attempts
were made to further control reflux in 4 of the 6 nonhealing
patients, which included both increasing proton pump in-
hibitor dose and hiatal hernia repair and fundoplication.
The fundoplication group underwent normal pH testing af-
ter surgery, but 2 of 3 patients still could not be successfully
ablated (Table 2). This observation calls the hypothesis of
poor reflux control into question.
CONCLUSIONS
We conducted a formal phase II clinical trial of RFA for
BE. This technology seems to eradicate BE in the majority
of cases when analyzed according to the intention to treat.
Problematic patients clearly seem to be those with large hi-
atal hernias and long columnar segments. Nonhealing rep-
resents a major cause of technical failure of this approach,
for which further investigation is needed. Although the ma-
jority of patients in the present trial had nondysplastic BE,
the role of RFA for patients without dysplasia outside of
a clinical trial remains unclear and worthy of further study.
References
1. O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dys-
plasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus
Registry. Am J Gastroenterol. 1999;94:2037-42.
2. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK,
et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J
Med. 2009;360:2277-88.
3. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Ten Kate FJ, Fockens P,
et al. Efficacy of radiofrequency ablation combined with endoscopic resection
for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol.
2010;8:23-9.
4. Van Vilsteren FGI, Pouw RE, Seewald S, Herrero LA, Sondermeijer CMT,
Visser M, et al. Stepwise radical endoscopic resection versus radiofrequency ab-
lation for Barrett’s Esophagus with high grade dysplasia or early cancer: a mul-
ticenter randomized trial. Gut. 2011;60:765-73.
5. Hernandez JC, Reicher S, Chung D, PhamBV, Tsai F, Disibio G, et al. Pilot series
of radiofrequency ablation of Barrett’s esophagus with or without neoplasia. En-
doscopy. 2008;40:388-92.
6. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofre-
quency energy ablation therapy for Barrett’s esophagus with and without dyspla-
sia. Dis Esophagus. 2007;20:516-22.
7. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, et al.
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s
esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:
185-95.gery c November 2011
Korst et al General Thoracic Surgery8. Gundrie JJ, PouwRE, Sondermeijer CM, Peters FP, CurversWL, RosmolenWD,
et al. Stepwise circumferential and focal ablation of Barrett’s esophagus with
high-grade dysplasia: results of the first prospective series of 11 patients. Endos-
copy. 2008;40:359-69.
9. Ganz RA, Overholt BF, Sharma VK, Fleischer DE, Shaheen NJ,
Lightdale CJ, et al. Circumferential ablation of Barrett’s esophagus that con-
tains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc.
2008;68:35-40.
10. Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett’s
esophagus: initial results and lessons learned. Surg Endosc. 2009;23:
2175-80.
11. Lyday WD, Corbett FS, Kuperman DA, Kalvaria I, Mavrelis PG, Shughoury AB,
et al. Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients
from a multicenter community practice registry. Endoscopy. 2010;42:272-8.COMMEN
From the Division of Cardiothoracic Surgery, University of North Carolina–Chapel
Hill, Chapel Hill, NC.
Disclosures: Author has nothing to disclose with regard to commercial support.
Received for publication July 31, 2011; accepted for publication Aug 25, 2011;
available ahead of print Aug 16, 2011.
Address for reprints: Nirmal Veeramachaneni, MD, Thoracic Surgery, University of
North Carolina–Chapel Hill, 3040 Burnett, Womack CB 7065, Chapel Hill, NC
27599 (E-mail: ; nirmalv@med.unc.edu).
J Thorac Cardiovasc Surg 2011;142:1173-4
0022-5223/$36.00
Copyright  2011 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2011.08.034
The Journal of Thoracic and Car12. Eldaif SM, Lin E, Singh KA, Force SD, Miller DL. Radiofrequency ablation of
Barrett’s esophagus: short-term results. Ann Thorac Surg. 2009;87:405-10.
13. Fleischer DE, Sharma VK. Endoscopic ablation of Barrett’s esophagus using the
HALO system. Dig Dis. 2008;26:280-4.
14. O’Connell K, Velanovich V. Effects of Nissen fundoplication on endoscopic en-
doluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2011;
25:830-4.
15. Zehetner J, DeMeester SR, Hagen JA, Ayazi S, Augustin F, Lipham JC, et al. En-
doscopic resection and ablation versus esophagectomy for high-grade dysplasia
and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:39-47.
16. Herrero LA, van Vilsteren FGI, Pouw RE, ten Kate FJW, Visser M,
Seldenrijk CA, et al. Endoscopic radiofrequency ablation combined with endo-
scopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm.
Gastrointest Endosc. 2011;73:682-90.TARY
G
T
SRadiofrequency ablation for nondysplastic Barrett’s esophagus:
Should we do it, because we can?Nirmal Veeramachaneni, MDThe treatment of patients with Barrett’s esophagus has
been a topic of intense investigation for the last several de-
cades. Although it is well recognized that Barrett’s esopha-
gus may develop into dysplasia and then progress to
invasive esophageal cancer, initial studies comparing fun-
doplication surgery and the best medical management avail-
able demonstrated no difference in either regression of the
Barrett’s esophagus or diminution of cancer risk.1 More
modern randomized, controlled trials that investigated lap-
aroscopic fundoplication or long-term proton pump inhibi-
tor use also did not demonstrate any regression of Barrett’s
esophagus with either strategy2 after 5 years of follow-up.
In fact, the American Gastroenterological Association
does not currently recommend routine surgery (fundoplica-
tion) to treat Barrett’s esophagus.3 Strategies to eradicate
Barrett’s esophagus by means of radiofrequency ablation
in patients with high-grade dysplasia, however, havedemonstrated efficacy in preventing the progression to
esophageal cancer.4
In the accompanying article in this issue of the Journal,
Korst and colleagues5 have extended the application of ra-
diofrequency ablation technology in a phase 2 trial of pa-
tients with Barrett’s esophagus without evidence of
dysplasia (72% of patients enrolled). This study demon-
strated efficacy in eradicating Barrett’s esophagus in 78%
of treated patients. Patients with large hiatal hernias were
found to be at risk for impaired healing of the esophageal
lining after radiofrequency ablation. This study provides
valuable information on the intensity of follow-up and treat-
ment necessary to treat Barrett’s esophagus with radio-
frequency ablation technology. There is considerable
variation with respect to the number of radiofrequency ab-
lation treatments needed, with as many as 5 treatments
needed for patients with less than 2 cm Barrett’s esophagus
and as many as 8 treatments needed for patients with greater
than 5 cm of Barrett’s esophagus. Treatments were done at
2-month intervals. Although the study patients have under-
gone careful endoscopic follow-up, the long-term efficacy
of the strategy remains unclear. Korst and colleagues5 are
unable to provide long-term follow-up data, and the rate
of recurrent Barrett’s esophagus is unknown. In addition,
there is no assessment for potential buried islands of Bar-
rett’s esophagus. Furthermore, given the low rate of pro-
gression of nondysplastic Barrett’s esophagus to cancer,
the utility of the intervention, even if successful, is unclear.diovascular Surgery c Volume 142, Number 5 1173
